PDF
File
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Vård & Omsorg |
Company Announcement
Monday, September 5, 2022, 10:00 CET
The information communicated in this announcement is "inside information" for the purposes of article 7 of the Market Abuse Regulation 596/2014
Brain + A/S ("Brain+") today announced Anders Härfstrand, who was elected to the board of directors at the company's Extraordinary General Meeting on September 2, 2022, has been appointed new Chairman of the Board. Anders Härfstrand has extensive international life science industry and leadership experience, and succeeds Lars Terney, who continues on the board as Vice Chairman after having served as Chairman for the past year.[ ]
"I feel very privileged to take on this role at such an exciting time for Brain+ and Digital Therapeutics industry. The needs of people living with dementia and their caregivers, health care systems, and regulators are changing rapidly. With our 2022 product launch of Cognitive Stimulation Therapy for therapists, Brain+ is navigating this complex environment in thoughtful, conscientious, and innovative ways." said Härfstrand.
Härfstrand brings to Brain+ 35 years of experience and a sustained successful global track record within global business development and new product commercialization in biotech and pharma. He has held chairman and board positions in numerous public life science companies and has significant leadership experience also from former chief executive roles in several leading pharmaceutical companies, including Pfizer. During his career, he successfully built product franchises in various therapeutic categories across the US, Japan, and the European Union. Härfstrand currently serves as Chairman at Diurnal Group (DNI) and as Non-Executive Director at Prothena Corporation (PRTA). Härfstrand is M.D. and PhD in neuroscience from the Karolinska Institute.
Following the Extraordinary General Meeting on 2 September 2022, the Brain+ board in addition to Anders Härfstrand also welcomes Johan Luthman, EVP & Head of R&D at Lundbeck, and Betül Susamis Unaran, Member of the Board of Directors of Ypsomed and Chief Strategy and Digital Officer at Zur Rose Group, as new board members. Both have world leading expertise in the fields of Alzheimer's disease and dementia and Digital Therapeutics.
Kim Baden-Kristensen, CEO and Co-founder of Brain+ said: "I am excited to be welcoming our three new highly experienced board members. Within Life Science, Digital Therapeutics, and dementia and Alzheimer's disease, Anders, Johan, and Betül are very heavy hitters who contribute significant expertise and international insights from across the pharmaceutical industry. With this strengthening of our board, Brain+ now has the leadership resources and competencies needed to optimally prepare for and execute on our commercialization and internationalization journey ahead".
Following the new additions, Brain+' Board of Directors will be comprised of Anders Härfstrand, Lars Terney, Johan Luthman, Betül Susamis Unaran, and Hanne Leth Hillman.- Anders Härstrand has been appointed Chairman also of the newly formed Chairmanship Committee and will be joined by Lars Terney as a member.
- Hanne Leth Hillman has been appointed Chairman of the newly formed Audit Committee and will be joined by Betül Susamis Unaran as a member.
Contact Information
CEO, Kim Baden-Kristensen + 45 31393317, E-mail: kim@brain-plus.com,Brain+ A/S, Købmagergade 53, 3.
Certified Advisor: Keswick Global AG, + 43 1 740 408045, E-mail: info@keswickglobal.com (%20info@keswickglobal.com)